Biolexis Therapeutics’ AMPK activator shows preclinical efficacy in obesity, type 2 diabetes
July 1, 2024
Biolexis Therapeutics Inc. is working on developing orally available, small-molecule AMPK activators that have been found to stimulate AMPK activity as well as dose-dependently enhance glucose uptake in human tissue.